2026 年可持续发展趋势报告 2026 Sustainability Trend Report Innovation or Impact Can a Greener Pharmaceutical Industry Have Both

SustainabilityReport2026

InnovationorImpact:

CanaGreenerPharmaceuticalIndustryHaveBoth?

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?2

Con

tents

03

07

Introduction

Chapterone:TheStateofInnovation

inPharmain2026?

15

ChapterTwo:TheEnvironmental

ImpactofPharmaceuticalInnovation

24

ChapterThree:SustainabilityasaCatalystforInnovation

31

ChapterFour:TheFuture-Can

PharmaAchieveBothInnovationandSustainability?

38

Conclusion

Introduction

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?4

Introduction

Thereisagrowingsenseacrossthepharmaceutical

industrythattwodefiningrealitiesarenolongerrunningalongsideoneanother,butarebeginningtocollide.

Thefirstistheextraordinarypaceofinnovation.

AIisreshapingdiscoveryanddevelopmentatremarkablespeed.Cellandgenetherapiesarepushingmedicine

intoterritoriesthatonlyveryrecentlyfeltspeculative.

Biologics,precisionmedicine,advancedanalytics,RNA

platforms,smartmanufacturing,andmoresophisticateddigitalinfrastructurearesteadilychangingnotonly

howtreatmentsaredeveloped,buthowdiseaseitselfisunderstood.

Thesecondistheunavoidablequestionofsustainability.

Butnotsustainabilityasbranding.OrasareportingexercisealignedneatlywithESGtargets.

Canthesystemsnowemergingacrosspharmaand

healthcaregenuinelyendureenvironmentally,operationally,economically,andsociallyovertime?Thatisthe

fundamentalquestion,andwhilethisisapharmaceuticalquestion,itisalsomuchbiggerthanpharma.

Theimplicationsstretchintohealthcaresystemsalreadyunderrealstrain.Intotheaffordabilityofmedicine.Into

Introduction

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?5

globalsupplychains.Intoenergydemand,manufacturinginfrastructure,computepower,procurement,regulation,

logistics,investmentandaccess.Intothelivespeoplemaybeabletoliveoverthenext10years.Howwelive.Howwellwelive.Whattreatmentsbecomepossibleandwhothosetreatmentsmayultimatelyreach.

ItisthereforenosurprisethatbodiessuchastheWorld

HealthOrganization(Introduction.1)andtheWorld

EconomicForum(Introduction.2)-alongsidescientific

institutes,policygroupsandsustainabilityorganisations

-arenowinvestingconsiderableattentionintothe

relationshipbetweenpharmaceuticalinnovationandlong-termenvironmentalviability.

Theconversationisnolongeraboutwhetherinnovationorsustainabilityshouldlead,butwhethertheindustry

cancontinuepursuingoneformofprogresswithoutfullyreckoningwiththeconsequencesoftheother.

AstheindustryapproachestheinauguralCPHI

SustainabilitySummitinMilan(Introduction.3),thereisclearlybothmomentumandappetiteforamore

openandhonestconversationaboutwhatsustainable

innovationmayactuallyneedinpractice.Thewillingnessofcontributorsacrossscience,manufacturing,procurement,sustainabilitystrategy,greenchemistry,biologics,AI

infrastructure,healthcareoperations,andclimateadvisory

toengageopenlywiththesubjecthasitselfbeennotable.Itisappositethatsustainabilityismovingtowardscentrestageatthemomentwhenthepharmaceuticalindustryitselfappearsonlytooawarethatinnovationnolonger

happensinisolatedsystems.

Thefurthercontributorstothisreportleantintothis

discussion,themoredifficultitbecametoseparate

innovationfrominfrastructure,manufacturingfromenergy,procurementfromemissionsvisibility,orsustainability

Introduction

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?6

fromthelong-termviabilityofpharmaceuticalsystems

themselves.Theperspectivesgatheredherearedrawn

fromindustryexpertresponsesandconversations

spanningscientific,operational,manufacturing,strategic,environmentalandcommercialdisciplines,exploring

howdifferentpartsofthepharmaceuticalecosystem

areapproachingthechallengeofbalancinginnovation

andsustainability.Together,theseperspectivesrevealanindustrynavigatingaprofoundtransitioninrealtime–onewhereopportunities,trade-offs,andunansweredquestionsincreasinglycoexist.

Somecontributorsbelievetheindustryisapproaching

agenuineturningpoint;thatsustainability-when

embeddedearlyenough-candrivebetterscience,

smartermanufacturingpathways,andmoreresilient

systems.Othersaremorecautious,citingtrade-offsalreadyemergingaround:infrastructuredependency,supplier

readiness,AIcomputedemand,cold-chainintensity,

manufacturingcomplexities,procurementpressure,andimplementationcapability.

Butmostrecognisethattheanswersareunlikelytocome

throughasingleEureka-stylemoment,butthrough

thousandsofco-dependentdecisionsmadeacross

complexsystemsovertime.Thisreportengagesthe

growingrecognitionthatoneofthemostimportant

questionsfacingpharmamayalsobecomeoneofthemost

definingindustrialquestionsofthenextdecade:howdo

wecontinuetoinnovateinwaysthatimproveandextendhumanlifewhilstensuringthesystemssupportingthat

progressremainviableforthefuturetheyaresupposedtoserve?

DavidRoach,

CreativeDirectorandCPHIOnlineContributor

Chapterone:

TheStateof

InnovationinPharmain2026

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?8

Chapter1:TheStateofInnovationinPharmain2026

Dealinginabsolutesisalwaysrisky.However,ifthereisadefiningcharacteristicofthepharmaceuticalindustryrightnow,itisnotsimplythespeedofinnovation,butthenumberofonce-separateworldsnowconvergingatthesametime.

AI,biologics,cellandgenetherapies,precisionmedicine,

advancedanalytics,smartmanufacturing,RNAplatforms,next-genlogistics,cloudinfrastructure,predictive

modelling,digitalsupplychains,andautomatedprocess

optimisationnolongersitquietlyattheedgeoftheindustry.Theyarenowmeldingandfunnellingintosomethingmuchlarger:apharmaceuticalecosystembecomingmoredata-driven,moretargeted,moretechnologicallyambitiousand,inmanyways,moreoperationallycomplexthanatany

pointinitshistory.

Andthemorecomplexitbecomes,theharderitbecomestoposition,explaincleanlyandnavigateeasily.

Thatdoesn’tmeanweshouldstoptrying.

Acrossindustryinsightsandconversations,thereisbroadagreementthatAInowsitsclosetothecentreofreal

andrapidtransformation.AIincreasinglyfeelslesslikeatool…andmorelikeaforcereshapingtheindustryaroundit.IsamirMartinezfromtheAmericanChemicalSociety,

Chapter1:TheStateofInnovationinPharmain2026

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?9

capturesthisshiftthroughthephrase“AIasFoundationalInfrastructure”,describinghowAIisnowembeddedacrossthepharmaceuticallifecycle,influencing:drugdiscovery;molecularmodelling;manufacturingoptimisation;

pharmacovigilance;regulatoryanalysis;andoperationaldecision-making.(1.1)

Thatphrasemattersbecausethis‘Foundational

Infrastructure’changesthenatureofdependency.OnceAIsystemsbecomedeeplyembeddedintopharmaceuticalR&Dandmanufacturingenvironments,innovationitself

beginsdependinguponanumberoffactors,including:

computeinfrastructure;cloudarchitecture;dataquality;modeltrainingcapability;energy-intensiveprocessingenvironments;anddigitalintegrationoperating

continuouslyinthebackground.

Thescaleofthepotentialisdizzying.Theoperationalimplicationsalreadyemergingareeye-opening.

Andperhapsonereasontheconversationaround

pharmaceuticalinnovationcurrentlyfeelssochargedisbecausemultipleformsofscientific,computational,manufacturing,andcommercialaccelerationarenowcollidingsimultaneously.

Previously,theseforcesoftenevolvedmoregraduallyandmoreseparately.Nowtheyincreasinglyarrivelayeredontopofoneanother.Theresultisanindustrybecoming

morecapable…butalsomoreoperationallydense.Andthisdensitymattersbecauseinnovationrarelyarrivesalone

anymore.Anewtherapyplatformmaythereforerequire:

evolvedsupplierecosystems;differentmanufacturing

environments;advancedcold-chaincapability;compute

infrastructure;soliddata-governancesystems;andaskilledworkforce.

Evenrelativelysmalladvancesinonepartofthe

pharmaceuticalecosystemcannowtriggersubstantial

operationalconsequenceselsewhere.Andcontributors

repeatedlyimplytheindustryisstilllearninghowtoabsorbthatlevelofsimultaneoustransformationcoherently.

Whilepharmaceuticalinnovationmayappearsomewhat

frictionlesspublicly,thesystemssupportingitarebecominganythingbut.

Onecontributordescribespharmaceuticalinnovationtodaylessasalinearprocessandmoreasaconstantlyevolvingoperationalecosystemwherediscovery,manufacturing,

logistics,dataenvironments,andsuppliercapability

increasinglymoveinparallel.Previously,pharmaceuticalorganisationscouldoftencompartmentalisecomplexity

moreeasily.R&Dhappenedinonespacewhile

manufacturingoccurredelsewhere.Procurement,logistics,regulatoryaffairs,andsustainabilityoftenoperatedin

comparativelyseparateoperationallanes.Contributors

Chapter1:TheStateofInnovationinPharmain2026

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?10

nowsuggestthoseseparationsarebecominghardertomaintain.

AndAIinvestmentmaybecome:

•acomputequestion;

•anenergyquestion;

•aprocurementquestion;

•andaninfrastructurequestionsimultaneously.Justasabiologicsplatformmaybecome:

•amanufacturingchallenge;

•acold-chainchallenge;

•awaste-managementchallenge;

•andasupplier-coordinationchallenge.

Thisinterconnectednessisonereasonseveralcontributorsreturntotheimportanceofsystems-awareness/systems-intelligenceratherthansimplyinnovationcapability

butalsounderstandingtheoperationalenvironments

innovationnowdependsupon.Thismightbeonereason

thepharmaceuticalindustrycurrentlyfeelsbothoptimisticanduneasy.Thescienceitselfismovingextraordinarily

quickly.Butthesystemssurroundingthescience-

infrastructure,regulation,energysystems,manufacturingcapability,supplierecosystems,andhealthcareeconomics-oftenevolvemoreslowly.

Thetensionbetweenthosetwospeedssitsunderneath

manyoftheconversationsshapingpharmatoday.Despitethescienceappearingalmostfrictionlessfromtheoutside,thesystemssupportingitrarelyare.

AI-drivenanalyticsintegratedwithgenomicsandmulti-

omicsplatformsareacceleratingmovementtowards

morepersonaliseddiagnosticsandtreatmentselection.

Earlierintervention,moretargetedtherapiesandfaster

developmentpathwaysarenotviewedasdistant

ambitions,butasactiveareasofprogress.Theyarealreadybeginningtoreshapepatientoutcomes.

Atthesametime,cellandgenetherapiescontinueto

occupyaparticularlysignificantspacewithintheindustry’simagination.Notsimplyascommercialopportunities,butastechnologiescapableoffundamentallyalteringtreatmentpathwaysfordiseasesthatuntilveryrecentlyhadlimited

options.

Chapter1:TheStateofInnovationinPharmain2026

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?11

BiologicsandRNA-basedplatformsareevolvingrapidlytoo.Pipelinesprogressivelyinclude:

•bi-specificantibodies;

•antibody-drugconjugates;

•engineeredcytokines;

•CAR-Ttherapies;

•gene-editingplatforms;

•andnext-genmRNAtechnologies.

Takentogether,theseadvancesarereshapingtreatmentexpectationsacrossoncology,immunology,andrare

diseaseparticularly.

Yetbeneaththisscientificmomentumsitsafarmore

complicated-andnotwhollyunexpected-reality:whilethescienceismovingonwithalacrity,thesystemssurroundingitareoftenstrugglingtoevolveatthesamepace.Thisis

wherecontributorslocatetension.

IsamirMartineznotesthatalthoughAIishelpingshorten

developmenttimelinesandimprovesafetymonitoring,

significantbarriersremainaroundthebroaderadoptionofadvancedtherapies.Assheobserves:“AccesschallengesremainespeciallyduetohighCGTcostsandunevenglobalinvestmentpatterns.”

Cellandgenetherapiesfrequentlyrequire:highly-

controlledcleanroomenvironments;specialistreagents;cryogenicstorage;lightlyregulatedmanufacturing

conditions;complexcold-chainlogistics;extensive

quality-controlsystems;andhighly-specialisedworkforcecapability.(1.2).

Together,theserequirementscreatechallengesthatextendfarbeyondscientificfeasibilityaloneandintoquestionsofscalability,affordability,andaccess.

Sometherapiesmayneedtobemanufacturedalmost

patient-by-patient,whichfundamentallyalterstraditionalassumptionsaroundmanufacturingscaleandefficiency.

Andwhilethesesystemsarebuiltforessentialreasons

-sterility,patientsafety,biologicalintegrity,regulatorycompliance-contributorspointouttheyalsocreateoperationalenvironmentswithexceptionallyhigh

infrastructuralintensity.

Chapter1:TheStateofInnovationinPharmain2026

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?12

KamiKrista-founderandCEOofElioEarth-goesfurtherstill.Hemotionsdirectlytowardstheenvironmental

implicationsattachednotonlytocleanroomintensityandcold-chainlogistics,buttothematerialfoundationsof

biologicsthemselves.

Virginfossil-derivedmaterialsremaindeeplyembedded

throughoutmanybiologicsmanufacturingenvironments.

(1.3).Single-usesystemscontinuegeneratingsubstantial

wastestreams.Andsomecellgrowthsystemscontinue

relyinguponinputssuchasfetalbovineserum(FBS),whoseemissionsintensitymaybeconsiderablyhigherthanmanyoutsidethesectorrealise.(1.4).

Thesearenotabstractsustainabilitydiscussions.Theyareoperationalrealitiesembeddeddeepinsideadvanced

therapeuticproduction.

KamiKristaalsoraisesanuncomfortable-butintellectuallyimportant-question:towhatlevelofenvironmentalburdenaresocietiesultimatelywillingtoabsorbinexchangefor

highlyresource-intensivetherapiestreatingrelativelysmallpatientpopulations?

Furthercontributionsmovedintoimplementationrealities,citingthatmanypharmaceuticalinnovationsnowarriveattachedtolargeoperationalecosystems.Innovationno

longerappearsseparablefromthesystemssupportingit.KamiKristareturnstothissystemsframing.

Innovation,hesuggests,isnotarrivingintostableor

isolatedenvironments.Itisarrivingintoenvironments

shapedby:computedependency;procurementpressure;manufacturingintensity;infrastructurefragility;regulatorycomplexity;climateexposure;supplierreadiness;and

increasinglyinterconnectedoperationalrisk.

Perhapsmoresignificantly,thesearesystemswheretheconsequencesofonedecisionincreasinglyripplefar

beyondtheoriginalpointofaction.

Traditionally,pharmaceuticalinnovationwasoften

discussedthroughtheboldlanguageofscientific

breakthrough:fasterdiscovery,strongerpipelines,greaterefficacy,andfirst-to-marketadvantage.

Somethingmorecomplicatedisemergingandinnovationislockedintosmallerfontsub-headings:manufacturinginfrastructure,energysystems,suppliercoordination,

lifecycleburden,logisticscapability,andlong-termoperationalsustainabilityitself.

KamiKrista’sownemphasis,however,islesson

Chapter1:TheStateofInnovationinPharmain2026

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?13

infrastructurestrainitselfandmoreonthedecisionsthat

shapelong-termoutcomes.Whilescientificbreakthroughsoftendominatediscussion,hearguesthatmanyofthe

choicesdeterminingamedicine’sfutureenvironment

footprintaremademuchearlierthroughmaterialselection,supplierchoice,processdesign,andmanufacturing

pathways.

Thechallengeisthatsustainabilityinformationfrequently

arrivestoolatetoinfluencethosedecisions.Bythetime

environmentalimpactsbecomefullyvisible,manyofthe

choicesthatwilldefineaproduct’slong-termfootprinthavealreadybeenmade.Ashenotes:“Itisbecomingessentialtoembedsustainabilityintotoday’sR&Dprocess”,particularlyifenvironmentalconsiderationsaretoinfluenceinnovationwhilethosedecisionsarestillbeingmade.

Viewedthisway,innovationisnotonlyaquestionof

scientificcapability.Itisaquestionofwhetherthe

information,tools,anddecision-makingprocessesguidingdevelopmentareevolvingquicklyenoughtoshapethe

outcomestheyultimatelyproduce.

AtAstraZeneca,RobertWilliams-SeniorDirector,

SustainableProcurement-describeshowlifecycle

assessment(LCA),carbonvisibility,SustainablebyDesign

principles-andotherwide-reachingAstraZenecainitiatives-arebeingintegratedfarearlierintodevelopment

pathways.(1.5).

Thegoalisnolongerjustmeasuringenvironmental

consequenceretrospectively,butidentifying,carbon

hotspots;materialintensity;manufacturingburden;

packagingimplications;supplierexposure;andenergydemandbeforemanufacturingsystemsandsupplierrelationshipsbecomecommerciallylockedin.

RobertWilliamsreturnstoonecentraltenet:manyofthe

technicalpathwaysalreadyexist.Thebiggerchallengeliesincoordinateddeliveryacrosslarge,independentsystems.

Ashesuggests:“Wealreadyhavemanyofthesolutionstothechallenge-wejustneedtoact.”

Inmanyareas,thelimitingfactornolongerappears

tobeawarenessalone,buttheoperationaldifficultyof

transformingsystemsalreadyfunctioningatextraordinaryscale.Thiscomplexityisincreasinglyvisiblearound

procurementtoo.

AtMerck,XimenaStawsky-SNOCoreMarketsHead

Biopharma,GlobalHealthcareOperationsHealthcare,

workingacrosshealthcareoperationsinbiopharma-

pointstowhatshedescribesasagrowingtensionbetweensustainabilityambitionandoperationaleconomics,

Chapter1:TheStateofInnovationinPharmain2026

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?14

particularlyonceinflationpressure,supplierfragilityandprocurementrealitiesentertheequation.

Oneexampleshereferences-attemptstoscalemore

sustainablecartonpalletsystems-revealedhow

commerciallyfragiletransitioncanbecomewhen

economicsfailtosupportimplementation.Assheputsit:

“Sustainabilityisexpected,butnotatapremium.”

Atfirstglance,itsoundslikeastraightforwardprocurementobservation.Butthechallengeappearsnotonly

technological,buteconomicandstructural.Whowillabsorbtheassociatedcosts?Orperhaps,asseveralcontributors

quietlyimply,theindustryisstillcollectivelylearninghowtoanswerthatnagging-buthugelyintegral-question.

Itisclearthatthepharmaindustryismovingthrougha

seismicandwidespreadtransition;onenotdrivenbya

singlebreakthrough,butbythecomingtogetherofarangeoffactorsincludingscientificacceleration,infrastructural

dependence,operationalcomplexity,digitaltransformation,manufacturingintensity,andenvironmentalconsequence.

Thereisnodoubtthatpharmaceuticalinnovationis

accelerating.Butthemoredifficultquestion-andone

castingalongshadowovertheindustry-iswhether

systemssurroundinginnovationareevolvingquickly

enoughtosupportitresponsiblyatscale?Ascontributors

increasinglysuggest,thatquestionbecomesharder

stillonceenergyintensity,materialdemand,compute

infrastructure,wateruse,andlong-termsustainabilityenterthediscussiondirectly.

Chaptertwo:

TheEnvironmental

Impactof

PharmaceuticalInnovation

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?16

ChapterTwo:TheEnvironmentalImpactofPharmaceuticalInnovation

Foralltheexcitementsurroundingthenextgenerationof

pharmaceuticalinnovation,anothersideofthestoryrefusestoremainquietlyandobedientlyinthebackground.For

behindeverybreakthroughtherapy,everyAI-powered

platform,everyadvancedmanufacturingenvironmentandeverytemperature-controlledshipmentsitssomethingelse:energyuse.

Historically,thepharmaceuticalindustryhasbeenjudged

primarilythroughthemedicinesitdevelopsandthelivesit

improves.Environmentalconsequences,wherediscussed

publiclyatall,oftensatsomewherefurtherdownstream.Againandagain,contributorssuggesttheindustrymaybeentering-orisactuallyin-aperiodwherethisseparationbecomes

hardertosustain,notbecausethevalueofinnovationisbeingquestioned,butbecausetheoperationalsystemsrequired

tosupportinnovationarebecominglarger,moreenergy-

intensive,andmoreenvironmentallyconsequentialthanmanyorganisationsperhapsanticipatedadecadeago.

Nowheredoesthistensionbecomemorevisiblethanaroundadvancedtherapies.Cellandgenetherapiesremainamongthemostscientificallyexcitingareasanywhereinmedicine.

Contributorsspeakofthemwithgenuineoptimism.Insome

cases,awe.Yetthefurthercontributorsmovedintooperationalrealities,themorecomplicatedthepicturebecame.

ChapterTwo:TheEnvironmentalImpactofPharmaceuticalInnovation

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?17

Thescienceitselfmaybeelegant.Thesystemssurroundingitoftenarenot.

Manyadvancedtherapiesdependupon:

•energy-intensivecleanrooms;

•tightly-regulatedairflowsystems;

•specialistreagents;

•cryogenicstorage;

•continuousrefrigeration;

environmentswithexceptionallyhighenvironmentalintensity.Thislandsbecausetheindustryisnowbeginningtoconfrontadifficultreality:someofthemostmedicallytransformativeinnovationsmayalsoproveamongthemostinfrastructure-heavy.Thisisnotareasontoabandonthem,butcontributorsfrequentlyimplyitmaybecomemoredifficulttoavoidthe

surroundingoperationalquestionsentirely.

Howshouldenvironmentalimpactbeunderstoodonce

treatmentbecomesresourceintensive?Whattrade-offs

becomeacceptableinhealthcareenvironments?Andperhapsmoreuncomfortably:howshouldtheindustrythinkabout

environmentalconsequencewhensometherapiesmaydramaticallyextendorimprovehumanlife?

•intricatecold-chainlogistics;

•extensivequality-controlinfrastructure;

•andlargevolumesofsingle-useplastics.(2.1).

Bigthemesemergehere.OnesthatKamiKristaofElioEarthrepeatedlyreturnstoasquestionsofconsequence,trade-

offandlong-termimpact.Anobservationaboutadvancedtherapies:“Itopensuptheuncomfortablequestionabouttheamountofenvironmentalimpactwearewillingtopay.”

Sometherapiesmayevenneedtobemanufacturedsemi-

individuallyaroundpatientsthemselves,radicallyaltering

assumptionsaroundmanufacturing,efficiencyandscale.

Whilethesesystemsexistforessentialreasons-patient

safety,sterility,biologicalintegrity,regulatorycompliance-

contributorsincreasinglysuggesttheyalsocreateoperational

Theproblemisnotthatpharmaceuticalinnovationhas

becomeenvironmentallyirresponsibleinanysimplisticsense.Itisthatinnovationnowoperatesinsidedeeplyinterconnectedindustrialsystemswhereenvironmentalburden,procurementpressure,infrastructuredependency,materialintensity,

computedemand,andoperationalconsequenceincreasinglyaccumulatesimultaneously.Thisisonereasoncontributors

ChapterTwo:TheEnvironmentalImpactofPharmaceuticalInnovation

SustainabilityReport2026InnovationorImpact:CanaGreenerPharmaceuticalIndustryHaveBoth?18

repeatedlyresistsimplisticsustainabilitynarratives.Unlike

manyconsumerindustries,pharmaceuticalsystemscannotsimplyoptimisearoundenvironmentalefficiencyalone.

Patientsafetyremainsnon-negotiable.Regulatorycomplianceremainsnon-negotiable.Sterilityremainsnon-negotiable.

Productintegrityremainsnon-negotiable.Thismeans

sustainabilityinterventioninsidepharmaceuticalenvironmentsoftenbecomesfarmoreoperationallycomplexthanpublic-

facingconversationssometimesimply.

Single-useplasticisagoodexample.Outsidepharmaceuticalmanufacturing,single-usesys